The effect of ticagrelor on growth of small abdominal aortic aneurysms-a randomized controlled trial
(2020) In Cardiovascular Research 116(2). p.450-456- Abstract
AIMS: To evaluate if ticagrelor, an effective platelet inhibitor without known non-responders, could inhibit growth of small abdominal aortic aneurysms (AAAs). METHODS AND RESULTS: In this multi-centre randomized controlled trial, double-blinded for ticagrelor and placebo, acetylic salicylic acid naïve patients with AAA and with a maximum aortic diameter 35-49 mm were included. The primary outcome was mean reduction in log-transformed AAA volume growth rate (%) measured with magnetic resonance imaging (MRI) at 12 months compared with baseline. Secondary outcomes include AAA-diameter growth rate and intraluminal thrombus (ILT) volume enlargement rate. A total of 144 patients from eight Swedish centres were randomized (72 in each group).... (More)
AIMS: To evaluate if ticagrelor, an effective platelet inhibitor without known non-responders, could inhibit growth of small abdominal aortic aneurysms (AAAs). METHODS AND RESULTS: In this multi-centre randomized controlled trial, double-blinded for ticagrelor and placebo, acetylic salicylic acid naïve patients with AAA and with a maximum aortic diameter 35-49 mm were included. The primary outcome was mean reduction in log-transformed AAA volume growth rate (%) measured with magnetic resonance imaging (MRI) at 12 months compared with baseline. Secondary outcomes include AAA-diameter growth rate and intraluminal thrombus (ILT) volume enlargement rate. A total of 144 patients from eight Swedish centres were randomized (72 in each group). MRI AAA volume increase was 9.1% for the ticagrelor group and 7.5% for the placebo group (P = 0.205) based on intention-to-treat analysis, and 8.5% vs. 7.4% in a per-protocol analysis (P = 0.372). MRI diameter change was 2.5 mm vs. 1.8 mm (P = 0.113), US diameter change 2.3 mm vs. 2.2 mm (P = 0.778), and ILT volume change 12.9% vs. 10.4% (P = 0.590). CONCLUSION: In this RCT, platelet inhibition with ticagrelor did not reduce growth of small AAAs. Whether the ILT has an important pathophysiological role for AAA growth cannot be determined based on this study due to the observed lack of thrombus modulating effect of ticagrelor. TRIAL REGISTRATION: The TicAAA trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT02070653.
(Less)
- author
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Abdominal aortic aneurysm, Anti-platelet treatment, Aortic diameter, Aortic volume, bleeding, Growth inhibitor, Intraluminal thrombus, Randomized controlled trial, Ticagrelor
- in
- Cardiovascular Research
- volume
- 116
- issue
- 2
- pages
- 7 pages
- publisher
- Oxford University Press
- external identifiers
-
- pmid:31135888
- scopus:85078506061
- ISSN
- 1755-3245
- DOI
- 10.1093/cvr/cvz133
- language
- English
- LU publication?
- no
- id
- ac797b47-6f97-4c9a-9988-23b743bdcac2
- date added to LUP
- 2020-02-05 08:50:49
- date last changed
- 2024-02-16 10:10:20
@article{ac797b47-6f97-4c9a-9988-23b743bdcac2, abstract = {{<p>AIMS: To evaluate if ticagrelor, an effective platelet inhibitor without known non-responders, could inhibit growth of small abdominal aortic aneurysms (AAAs). METHODS AND RESULTS: In this multi-centre randomized controlled trial, double-blinded for ticagrelor and placebo, acetylic salicylic acid naïve patients with AAA and with a maximum aortic diameter 35-49 mm were included. The primary outcome was mean reduction in log-transformed AAA volume growth rate (%) measured with magnetic resonance imaging (MRI) at 12 months compared with baseline. Secondary outcomes include AAA-diameter growth rate and intraluminal thrombus (ILT) volume enlargement rate. A total of 144 patients from eight Swedish centres were randomized (72 in each group). MRI AAA volume increase was 9.1% for the ticagrelor group and 7.5% for the placebo group (P = 0.205) based on intention-to-treat analysis, and 8.5% vs. 7.4% in a per-protocol analysis (P = 0.372). MRI diameter change was 2.5 mm vs. 1.8 mm (P = 0.113), US diameter change 2.3 mm vs. 2.2 mm (P = 0.778), and ILT volume change 12.9% vs. 10.4% (P = 0.590). CONCLUSION: In this RCT, platelet inhibition with ticagrelor did not reduce growth of small AAAs. Whether the ILT has an important pathophysiological role for AAA growth cannot be determined based on this study due to the observed lack of thrombus modulating effect of ticagrelor. TRIAL REGISTRATION: The TicAAA trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT02070653.</p>}}, author = {{Wanhainen, Anders and Mani, Kevin and Kullberg, Joel and Svensjö, Sverker and Bersztel, Adam and Karlsson, Lars and Holst, Jan and Gottsäter, Anders and Linné, Anneli and Gillgren, Peter and Langenskiöld, Marcus and Hultgren, Rebecka and Roy, Joy and Gilgen, Nils Peter and Ahlström, Håkan and Lederle, Frank A. and Björck, Martin}}, issn = {{1755-3245}}, keywords = {{Abdominal aortic aneurysm; Anti-platelet treatment; Aortic diameter; Aortic volume; bleeding; Growth inhibitor; Intraluminal thrombus; Randomized controlled trial; Ticagrelor}}, language = {{eng}}, number = {{2}}, pages = {{450--456}}, publisher = {{Oxford University Press}}, series = {{Cardiovascular Research}}, title = {{The effect of ticagrelor on growth of small abdominal aortic aneurysms-a randomized controlled trial}}, url = {{http://dx.doi.org/10.1093/cvr/cvz133}}, doi = {{10.1093/cvr/cvz133}}, volume = {{116}}, year = {{2020}}, }